Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BCT013
MIFTS: 48

Bacterial Pneumonia

Categories: Infectious diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Bacterial Pneumonia

About this section

MalaCards integrated aliases for Bacterial Pneumonia:

Name: Bacterial Pneumonia 12 74 15 17
Pneumonia Due to Other Gram-Negative Bacteria 12
Gram-Negative Pneumonia 12
Pneumonia, Bacterial 43
Pneumonia Bacterial 54

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Respiratory diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:874
ICD9CM 34 482.9
MeSH 43 D018410
NCIt 49 C26704
SNOMED-CT 67 53084003
ICD10 32 J15 J15.9
UMLS 71 C0004626
Sources

Summaries for Bacterial Pneumonia

About this section
Disease Ontology : 12 A pneumonia involving inflammation of the lungs caused by bacteria.

MalaCards based summary : Bacterial Pneumonia, also known as pneumonia due to other gram-negative bacteria, is related to mycoplasma pneumoniae pneumonia and aspiration pneumonia. An important gene associated with Bacterial Pneumonia is CRP (C-Reactive Protein), and among its related pathways/superpathways are Innate Immune System and IL-17 Family Signaling Pathways. The drugs Tobramycin and Vancomycin have been mentioned in the context of this disorder. Affiliated tissues include lung, neutrophil and testes.

Wikipedia : 74 Bacterial pneumonia is a type of pneumonia caused by bacterial... more...

Sources

Related Diseases for Bacterial Pneumonia

About this section

Diseases in the Pneumonia family:

Viral Pneumonia Bacterial Pneumonia

Diseases related to Bacterial Pneumonia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 487)
# Related Disease Score Top Affiliating Genes
1 mycoplasma pneumoniae pneumonia 33.5 SFTPD IL6 CRP
2 aspiration pneumonia 33.2 IL6 GPT CRP
3 chlamydia pneumonia 33.1 TLR4 IL6 CXCL8 CRP
4 streptococcus pneumonia 33.1 TLR4 IL6 CXCL8 CRP
5 pneumonia 31.5 TLR4 SLPI SFTPD SFTPB SCGB1A1 IL6
6 chlamydia 31.4 TLR4 IL6 CXCL8 CRP
7 viral pneumonia 31.3 SFTPD IL6 CXCL8 CRP
8 bacterial infectious disease 31.1 TLR4 IL6 ELANE DEFB4A CXCL8 CSF3
9 bronchiectasis 31.0 SLPI ELANE CXCL8 CRP
10 toxic shock syndrome 31.0 TLR4 IL6 HMGB1 CXCL8 CRP
11 pulmonary edema 31.0 SCGB1A1 CXCL8 CSF3 CRP
12 covid-19 31.0 IL6 GPT CRP
13 oral candidiasis 30.8 SLPI DEFB4A CXCL8
14 pulmonary tuberculosis 30.8 TLR4 IL6 CRP CCL3
15 bronchopneumonia 30.8 TLR4 IL6 GPT ELANE CXCL8 CRP
16 eosinophilic pneumonia 30.7 SFTPD IL6 CXCL8
17 neutropenia 30.7 TLR4 IL6 GPT ELANE CXCL8 CSF3
18 pneumocystosis 30.6 SFTPD IL6 CSF3 CRP
19 exanthem 30.6 IL6 GPT CXCL8 CSF3 CRP
20 endocarditis 30.6 IL6 CXCL8 CRP
21 diarrhea 30.6 TLR4 IL6 GPT CXCL8 CXCL1 CSF3
22 disseminated intravascular coagulation 30.6 IL6 HMGB1 GPT ELANE CRP
23 fasciitis 30.6 IL6 CXCL8 CRP
24 pasteurellosis 30.5 SLPI ELANE CXCL8
25 invasive aspergillosis 30.5 TLR4 SFTPD CXCL8 CSF3
26 coronavirus infectious disease 30.5 IL6 CXCL8 CRP
27 respiratory syncytial virus infectious disease 30.5 SFTPB CCL3
28 pericarditis 30.5 IL6 CXCL8 CRP
29 pericardial effusion 30.5 IL6 GPT CRP
30 candidiasis 30.5 TLR4 IL6 IL22 DEFB4A CXCL8
31 pulmonary fibrosis 30.5 SFTPD ELN ELANE CXCL8 CCL3
32 respiratory failure 30.5 TLR4 SFTPD SFTPB SCGB1A1 IL6 GPT
33 acute cholangitis 30.5 IL6 GPT CRP CALCA
34 peritonitis 30.4 TLR4 IL6 HMGB1 ELANE CXCL8 CSF3
35 avian influenza 30.4 SFTPD IL6 CXCL8
36 severe acute respiratory syndrome 30.4 IL6 GPT CXCL8 CRP CCL3
37 varicose veins 30.3 IL6 ELN CXCL8
38 aspergillosis 30.3 TLR4 SFTPD IL6 ELANE CXCL8 CSF3
39 thrombocytosis 30.3 IL6 CSF3 CRP
40 bacterial meningitis 30.3 TLR4 IL6 CXCL8 CXCL1 CRP
41 mycobacterium tuberculosis 1 30.3 TLR4 DEFB4A CRP CCL3
42 sarcoidosis 1 30.3 SFTPD SCGB1A1 CRP CCL3
43 cholangitis 30.3 TLR4 IL6 GPT CXCL8 CRP
44 pulmonary hypertension 30.3 IL6 ELANE CXCL8 CRP CALCA
45 celiac disease 1 30.3 TLR4 IL6 CXCL8 CRP
46 meningitis 30.3 TLR4 IL6 CXCL8 CXCL1 CSF3 CRP
47 osteomyelitis 30.3 TLR4 IL6 CXCL8 CSF3 CALCA
48 gastritis 30.3 TLR4 IL6 DEFB4A CXCL8 CXCL1
49 hyper ige syndrome 30.3 TLR4 IL6 CXCL8
50 adult respiratory distress syndrome 30.2 SFTPD SFTPB IL6 ELN ELANE CXCL8

Graphical network of the top 20 diseases related to Bacterial Pneumonia:



Diseases related to Bacterial Pneumonia
Sources

Symptoms & Phenotypes for Bacterial Pneumonia

About this section
Sources

Drugs & Therapeutics for Bacterial Pneumonia

About this section

Drugs for Bacterial Pneumonia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 196)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
2
Vancomycin Approved Phase 4 1404-90-6 14969 441141
3
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
4
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
5
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
6
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
7
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
10
Zidovudine Approved Phase 4 30516-87-1 35370
11
Nevirapine Approved Phase 4 129618-40-2 4463
12
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
13
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
14
Acetaminophen Approved Phase 4 103-90-2 1983
15
Hydroxychloroquine Approved Phase 4 118-42-3 3652
16
Ceftriaxone Approved Phase 4 73384-59-5 5361919 5479530
17
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
18
Ofloxacin Approved Phase 4 82419-36-1 4583
19
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
20
Ribavirin Approved Phase 4 36791-04-5 37542
21
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
22
protease inhibitors Phase 4
23 HIV Protease Inhibitors Phase 4
24 Cephalosporins Phase 4
25 Trace Elements Phase 4
26 Micronutrients Phase 4
27 Hormones Phase 4
28 Amoxicillin-Potassium Clavulanate Combination Phase 4
29 Gastrointestinal Agents Phase 4
30 Vaccines Phase 4
31 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
32 Immunologic Factors Phase 4
33 Anti-Inflammatory Agents Phase 4
34 Antineoplastic Agents, Hormonal Phase 4
35 Hormone Antagonists Phase 4
36 Antiemetics Phase 4
37 glucocorticoids Phase 4
38 Clindamycin phosphate Phase 4
39 Clindamycin palmitate Phase 4
40 MF59 oil emulsion Phase 4
41 BB 1101 Phase 4
42 Anti-Retroviral Agents Phase 4
43 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
44 Liver Extracts Phase 4
45 Antibiotics, Antitubercular Phase 4
46 Antiprotozoal Agents Phase 4
47 Antiparasitic Agents Phase 4
48 Antimalarials Phase 4
49 Antirheumatic Agents Phase 4
50 Lactams Phase 4

Interventional clinical trials:

(show top 50) (show all 204)
# Name Status NCT ID Phase Drugs
1 Individualizing Duration of Antibiotic Therapy in Hospitalized Patients With Community - Acquired Pneumonia: a Non-inferiority, Randomized, Controlled Trial. Unknown status NCT01492387 Phase 4
2 Ventilator Associated Pneumonia: Addition of Tobramycin Inhalation Antibiotic Treatment to Standard IV Antibiotic Treatment Unknown status NCT02440828 Phase 4 tobramycin inhalation;placebo
3 Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia (CABP) Completed NCT01524302 Phase 4 Ceftaroline;Levofloxacin
4 A Multicenter, Multinational, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil Versus Ceftriaxone Plus Vancomycin in Adult Subjects With Community-acquired Bacterial Pneumonia at Risk for Infection Due to Methicillin-resistant Staphylococcus Aureus Completed NCT01645735 Phase 4 Ceftaroline fosamil;Ceftriaxone plus vancomycin
5 Title: Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia During the Influenza Season (U18) Completed NCT01248715 Phase 4 oseltamivir
6 Phase 4 Randomized Multicentric Controlled Study on Impact of Continuous Venovenous Hemofiltration on Organ Failure at the Early Phase of Severe Sepsis Completed NCT00406198 Phase 4
7 A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone Plus Vancomycin in Pediatric Subjects With Complicated Community-acquired Bacterial Pneumonia (CABP) Completed NCT01669980 Phase 4 Ceftaroline fosamil;IV Ceftriaxone and Vancomycin
8 Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy Completed NCT00402805 Phase 4
9 A Randomized Controlled Trial Comparing Adjuvanted vs. Nonadjuvanted Influenza Vaccine in Adult Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients. Completed NCT02560909 Phase 4
10 A Comparative, Randomised Controlled Trial for Evaluating the Efficacy of Dexamethasone in the Treatment of Patients With Acute Respiratory Distress Syndrome Completed NCT01731795 Phase 4 Dexamethasone
11 Randomized, Controlled Clinical Trial of Day-care Based and Hospitalized Management of Severe and Very Severe Pneumonia, With Severe Malnutrition, With/Without Associated Co-morbidities in Children Completed NCT00968370 Phase 4
12 A Randomised Controlled Trial Comparing Two-Dose Priming With the 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks to 6 and 14 Weeks in Nepali Children Completed NCT02385513 Phase 4
13 Shortened Antibiotic Treatment in Community-Acquired Pneumonia: A Nationwide Danish Randomized Controlled Trial Recruiting NCT04089787 Phase 4
14 Evaluation of World Health Organization (WHO) Recommendations on Test and Treat Strategy, Managing Advanced HIV Disease and Rapid Initiation of ART Among People Living With HIV in Nepal: A Cluster Randomized Trial. Active, not recruiting NCT03723525 Phase 4
15 Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial Not yet recruiting NCT04382625 Phase 4 Hydroxychloroquine
16 Comparison Between Ceftriaxone and Levofloxacin on Cytokine Expression Over Time in Severe Pneumococcal Pneumonia Terminated NCT00429975 Phase 4 levofloxacin;ceftriaxone
17 Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon Terminated NCT00687544 Phase 4 Ribavirin (SCH 018908)
18 A Multicenter Study to Describe the Safety and Efficacy of Ceftaroline Fosamil in Elderly Subjects With Community-Acquired Bacterial Pneumonia Withdrawn NCT01666743 Phase 4 Ceftaroline fosamil
19 Randomized Aseptic Pharmacokinetic Pharmacodynamic Outpatient Registry Trial of Respiratory Tract Infections in Adults (RAPPORT) Withdrawn NCT00245453 Phase 4 azithromycin;telithromycin;Clarythromycin
20 A Phase III Study to Evaluate the Efficacy and Safety of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia Unknown status NCT01937832 Phase 3 Faropenem;Ertapenem
21 The Effect of Ulinastatin on Bronchoalveolar Lavage Fluid of Inflammatory Factors in Patients With Ventilator-associated Pneumonia Unknown status NCT01865266 Phase 2, Phase 3 Ulinaststin for injection;placebo
22 Phase 3b Randomized Double Blind Controled Placebo Comparative Trial of Intravenous Colistin vs Intravenous Colistin Plus Nebulized Colistin in Patients With Ventilator-associated Pneumonia (VAP) Due Multiresistant Acinetobacter Baumanii Unknown status NCT00645723 Phase 3 Colistin;Colistin and saline solution
23 Randomized Controlled Trial of Intramuscular Ceftriaxone Versus Procaine Penicillin Versus Cotrimoxazole and Gentamicin for Management of Serious Bacterial Infections in Young Infants in Community Settings Unknown status NCT00189384 Phase 3 ceftriaxone, procaine penicillin and gentamicin, oral cotrimoxazole and gentamicin
24 Safety and Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine Among Solid Organ Transplant Recipients: Protocol 1A and 1B Unknown status NCT00213265 Phase 3
25 A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients With Gram-Negative Pneumonia Completed NCT01799993 Phase 3 Amikacin Inhalation Solution (BAY41-6551);Aerosolized Placebo
26 Study of Cidecinâ„¢ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae Completed NCT00540072 Phase 3 daptomycin
27 A Randomized, Double-Blind, Phase III, Comparative Study of Cidecinâ„¢ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae Completed NCT00538694 Phase 3 daptomycin
28 A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Tigecycline Vs Imipenem/Cilastatin For The Treatment Of Subjects With Nosocomial Pneumonia Completed NCT00080496 Phase 3 Tigecycline;Imipenem;Cilastatin
29 A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Intravenous Tigecycline Vs Intravenous Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia Completed NCT00081575 Phase 3 Tigecycline;Levofloxacin
30 A Multicenter, Unblinded, Non-Comparative Study Of Unasyn-S 12 G/Day Evaluating The Safety And Efficacy In Japanese Adult Subjects With Community Acquired Pneumonia Completed NCT01189487 Phase 3 ampicillin sodium/sulbactam sodium
31 A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia Completed NCT02531438 Phase 3 Omadacycline;Moxifloxacin
32 A Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia Completed NCT01371838 Phase 3 Ceftaroline;Ceftriaxone
33 A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Tigecycline Vs Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia Completed NCT00079885 Phase 3 tigecycline
34 A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus Completed NCT00107952 Phase 3 Telavancin;Vancomycin
35 A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus Completed NCT00124020 Phase 3 Telavancin;Vancomycin
36 Ceftaroline Fosamil Versus Standard of Care for Community Acquired Bacterial Pneumonia (CABP): Clinical Outcomes Among Hospitalized Adults at a Single United States Hospital Completed NCT01605864 Phase 3 Efficacy of ceftaroline
37 A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects With Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia Completed NCT02493764 Phase 3 Imipenem;Relebactam;Cilastatin;Piperacillin;Tazobactam;Linezolid
38 A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Adult Patients With Community-Acquired Bacterial Pneumonia Completed NCT01968733 Phase 3 Solithromycin;Moxifloxacin
39 A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in the Treatment of Adult Patients With Community-Acquired Bacterial Pneumonia Completed NCT01756339 Phase 3 Solithromycin;Moxifloxacin
40 A Phase 3, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety and Efficacy of Intravenous to Oral Delafloxacin in Adult Subjects With Community-Acquired Bacterial Pneumonia Completed NCT02679573 Phase 3 Delafloxacin;Moxifloxacin;Linezolid
41 A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone in Pediatric Subjects With Community-acquired Bacterial Pneumonia Requiring Hospitalization Completed NCT01530763 Phase 2, Phase 3 Ceftaroline fosamil;Ceftriaxone;amoxicillin clavulanate
42 A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE) Completed NCT01970371 Phase 3 plazomicin;colistin;meropenem;tigecycline;antibiotic of Investigator's choice
43 A Prospective, Non-randomized, Open-label, Non-controlled, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics/ Pharmacodynamics of BAYQ3939 (400 mg BID and TID) in Hospitalized Patients With Bacterial Pneumonia or Secondary Infection of Chronic Respiratory Disease With Severe Disease or a Poor Response to Other Antimicrobials Completed NCT01561794 Phase 3 Ciprofloxacin (Cipro, BAYQ3939)
44 Randomized, Open Label, Multicenter, Non-inferiority Trial to Compare Safety and Efficacy of Colistin vs. Meropenem in VAP Caused by CR-GNB Completed NCT01292031 Phase 3 Colistin;Meropenem
45 A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone in the Treatment of Adult Subjects With Community-Acquired Pneumonia Completed NCT00509106 Phase 3 Ceftaroline fosamil for Injection;Ceftriaxone;Placebo
46 Acute Respiratory Infections and Asthma in U-5 Children: Improved Treatment to Reduce Morbidity and Mortality in Uganda, A Randomized Controlled Trial Completed NCT01868113 Phase 3 Inhaled corticosteroid
47 Parapneumonic Effusion in Children Study Completed NCT00202826 Phase 3
48 A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone, With Adjunctive Clarithromycin, in the Treatment of Adult Subjects With Community-Acquired Pneumonia Completed NCT00621504 Phase 3 Ceftaroline fosamil for Injection;IV Ceftriaxone;Placebo;Clarithromycin
49 An International, Multicenter, Randomized, Double-blind, Double-dummy, Two-way, Parallel Group, Controlled Study to Compare the Efficacy and Safety of Intravenous and Oral Nemonoxacin Versus Tavanic® in Adult Patients With Community-acquired Pneumonia Completed NCT03551210 Phase 3 Nemonoxacin;Nemonoxacin;Tavanic;Tavanic;Placebo (250 ml);Placebo (100 ml)
50 A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE) Completed NCT02168946 Phase 3 Vabomere;Best Available Therapy

Search NIH Clinical Center for Bacterial Pneumonia

Cochrane evidence based reviews: pneumonia, bacterial

Sources

Genetic Tests for Bacterial Pneumonia

About this section
Sources

Anatomical Context for Bacterial Pneumonia

About this section

MalaCards organs/tissues related to Bacterial Pneumonia:

40
Lung, Neutrophil, Testes, Skin, Colon, Liver, Bone
Sources

Publications for Bacterial Pneumonia

About this section

Articles related to Bacterial Pneumonia:

(show top 50) (show all 3647)
# Title Authors PMID Year
1
Myeloperoxidase-dependent inactivation of surfactant protein D in vitro and in vivo. 54 61
20228064 2010
2
2009 influenza A (H1N1): a clinical review. 61 54
20469616 2010
3
MyD88-dependent TLR4 signaling is selectively impaired in alveolar macrophages from asymptomatic HIV+ persons. 54 61
20197549 2010
4
Prognostic value of C-reactive protein in HIV-infected patients with Pneumocystis jirovecii pneumonia. 54 61
20378904 2010
5
Is procalcitonin better than C-reactive protein for early diagnosis of bacterial pneumonia in children? 61 54
20087955 2010
6
Validity of the quick-read C-reactive protein test in the prediction of bacterial pneumonia in the pediatric emergency department. 61 54
18460957 2008
7
The utility of serum C-reactive protein in differentiating bacterial from nonbacterial pneumonia in children: a meta-analysis of 1230 children. 61 54
18174874 2008
8
Evaluation of serum amyloid A and surfactant protein D in sera for identification of the clinical condition of horses with bacterial pneumonia. 61 54
17827889 2007
9
Procalcitonin versus C-reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care. 54 61
17727748 2007
10
[Changes and clinical significance of Toll-like receptor 2 and 4 expression in neonatal infections]. 61 54
17456342 2007
11
Disease severity in patients with simultaneous influenza and bacterial pneumonia. 54 61
17603232 2007
12
[Clinical features and outcome in 84 patients with influenza pneumonia]. 61 54
17087332 2006
13
Neutrophil serine proteinases inactivate surfactant protein D by cleaving within a conserved subregion of the carbohydrate recognition domain. 61 54
15078883 2004
14
C-reactive protein in the diagnosis of community-acquired pneumonia. 54 61
14533984 2003
15
Correlations between serum amyloid A protein and C-reactive protein in infectious diseases. 54 61
12940634 2003
16
Bacterial pneumonia can increase serum concentration of clozapine. 54 61
12185555 2002
17
Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. 54 61
11818324 2002
18
Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. 61 54
11588011 2001
19
Procalcitonin in children admitted to hospital with community acquired pneumonia. 61 54
11259234 2001
20
Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children. 61 54
10917215 2000
21
[A study of human beta-defensin-1 and human beta-defensin-2 in airway mucosal defense]. 54 61
10213993 1999
22
[Significance of serum surfactant protein-D (SP-D) level in patients with pulmonary tuberculosis]. 54 61
9844346 1998
23
Identification of human beta-defensin-2 in respiratory tract and plasma and its increase in bacterial pneumonia. 61 54
9731241 1998
24
Value of C-reactive protein in the detection of bacterial contamination at the time of presentation in drug-induced aspiration pneumonia. 61 54
9266885 1997
25
[Diagnostic value of serum soluble interleukin-2 receptor levels in interstitial pneumonia of the patients with hematological disorders]. 54 61
9059070 1997
26
Adenosine deaminase activity in the aetiological diagnosis of community-acquired pneumonia. 61 54
9255891 1997
27
[A comparative study of tazobactam/piperacillin and piperacillin in bacterial pneumonia]. 54 61
7783313 1995
28
Possible low response of C-reactive protein production in eosinophilic pneumonia. 61 54
8735434 1995
29
[Diagnostic value of C-reactive protein in comparison with erythrocyte sedimentation as routine admission diagnostic test]. 54 61
7878400 1995
30
Utility of C-reactive protein measurements for empyema diagnosis after pneumonectomy. 61 54
8166544 1994
31
The C-reactive protein responses in HIV-infected patients with pneumonia. 61 54
8362226 1993
32
[Studies on risk factors influencing delayed resolution of pneumonia]. 54 61
1294663 1992
33
Efficacy and safety of loracarbef in the treatment of pneumonia. 61 54
1621747 1992
34
[Pneumonia caused by Moraxella subgenus Moraxella sp]. 61 54
1624833 1992
35
Adenosine deaminase activity and free IL-2 receptor levels in serum from patients with mycoplasma pneumonia. 61 54
1907690 1991
36
The Association of Antibiotic Duration With Successful Treatment of Community-Acquired Pneumonia in Children. 61
32525203 2020
37
Hypercapnia Suppresses Macrophage Antiviral Activity and Increases Mortality of Influenza A Infection via Akt1. 61
32540997 2020
38
The rapid photoresponsive bacteria-killing of Cu-doped MoS2. 61
32578588 2020
39
Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. 61
32211756 2020
40
Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis. 61
32524516 2020
41
Outcomes among HIV-positive patients hospitalized with COVID-19. 61
32568770 2020
42
Covid-19: automatic detection from X-ray images utilizing transfer learning with convolutional neural networks. 61
32524445 2020
43
Is there any supportive evidence for low dose radiotherapy for COVID-19 pneumonia? 61
32579043 2020
44
Bacterial Pneumonia in COVID-19 critically ill patients: a case series. 61
32544219 2020
45
CoroNet: A deep neural network for detection and diagnosis of COVID-19 from chest x-ray images. 61
32534344 2020
46
Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): data from the delafloxacin phase 3 CABP trial. 61
32534142 2020
47
Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. 61
32291399 2020
48
Lefamulin: The First Systemic Pleuromutilin Antibiotic. 61
32493034 2020
49
Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data. 61
32340986 2020
50
Aminoglycosides in Immunocompromised Critically Ill Patients with Bacterial Pneumonia and Septic Shock: A Post-Hoc Analysis of a Prospective Multicenter Multinational Cohort. 61
32496415 2020
Sources

Variations for Bacterial Pneumonia

About this section
Sources

Expression for Bacterial Pneumonia

About this section
Search GEO for disease gene expression data for Bacterial Pneumonia.
Sources

Pathways for Bacterial Pneumonia

About this section

Pathways related to Bacterial Pneumonia according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.9 TLR4 SLPI S100A12 IL6 IL22 HMGB1
2
IL-17 Family Signaling Pathways 64
Show member pathways
 12.24 IL6 DEFB4A CXCL8 CXCL1 CSF3
3
Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.21 IL6 CXCL8 CXCL1 CCL3
4
NOD-like receptor signaling pathway 36
12.11 TLR4 IL6 DEFB4A CXCL8 CXCL1
5
Bacterial infections in CF airways 22
Show member pathways
 12.05 TLR4 SFTPD IL6 DEFB4A CXCL8
6
Spinal Cord Injury 1
11.94 TLR4 IL6 CXCL8 CXCL1
7
Senescence and Autophagy in Cancer 1
11.86 IL6 CXCL8 CXCL1 CCL3
8
Amoebiasis 36
11.83 TLR4 IL6 CXCL8 CXCL1
9
Th17 Differentiation 64
Show member pathways
 11.73 TLR4 IL6 IL22
10
Pertussis 36
11.64 TLR4 IL6 CXCL8
11
Rheumatoid arthritis 36
11.62 TLR4 IL6 CXCL8 CXCL1 CCL3
12
Cytokine production by Th17 cells in CF (Mouse model) 22
Show member pathways
 11.52 TLR4 IL6 CXCL8 CXCL1 CSF3
13
Legionellosis 36
11.43 TLR4 IL6 CXCL8 CXCL1
14
amb2 Integrin signaling 1
11.42 IL6 HMGB1 ELANE
15
Malaria 36
11.32 TLR4 IL6 CXCL8 CSF3
16
Cytokines and Inflammatory Response 1
11.19 IL6 CXCL1 CSF3
17
Interleukin-10 signaling 65
11.04 IL6 CXCL8 CXCL1 CSF3 CCL3
18
Overview of nanoparticle effects 1
10.93 IL6 CXCL8 CRP
19
Lung fibrosis 1
10.9 IL6 ELN CXCL8 CSF3 CCL3 CALCA
20
G-protein signaling_Rap2B regulation pathway 22
10.85 IL6 IL22 ELN CXCL8 CXCL1 CSF3
21
Advanced glycosylation endproduct receptor signaling 65
10.71 S100A12 HMGB1
Sources

GO Terms for Bacterial Pneumonia

About this section

Cellular components related to Bacterial Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.89 SLPI SFTPD SFTPB SCGB1A1 S100A12 IL6
2 extracellular space GO:0005615 9.53 SLPI SFTPD SFTPB SCGB1A1 IL6 IL22
3 specific granule lumen GO:0035580 9.33 SLPI ELANE CXCL1

Biological processes related to Bacterial Pneumonia according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.09 TLR4 SLPI SFTPD S100A12 MARCO HMGB1
2 neutrophil degranulation GO:0043312 10.04 SLPI S100A12 HMGB1 ELANE CXCL1
3 innate immune response GO:0045087 9.98 TLR4 SLPI SFTPD S100A12 MARCO HMGB1
4 cellular protein metabolic process GO:0044267 9.93 SFTPD SFTPB IL6 CALCA
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.92 TLR4 MARCO HMGB1 CCL3
6 response to lipopolysaccharide GO:0032496 9.89 TLR4 SLPI SCGB1A1 ELANE
7 cytokine-mediated signaling pathway GO:0019221 9.85 IL6 IL22 CXCL8 CXCL1 CSF3 CCL3
8 cell chemotaxis GO:0060326 9.83 HMGB1 DEFB4A CCL3
9 defense response to Gram-negative bacterium GO:0050829 9.83 TLR4 IL6 DEFB4A
10 chemokine-mediated signaling pathway GO:0070098 9.8 CXCL8 CXCL1 CCL3
11 chemotaxis GO:0006935 9.8 HMGB1 DEFB4A CXCL8 CXCL1 CCL3
12 response to glucocorticoid GO:0051384 9.79 SCGB1A1 IL6 IL22
13 positive regulation of interleukin-6 production GO:0032755 9.78 TLR4 IL6 HMGB1
14 neutrophil chemotaxis GO:0030593 9.78 S100A12 CXCL8 CXCL1 CCL3
15 positive regulation of tumor necrosis factor production GO:0032760 9.77 TLR4 HMGB1 CCL3
16 positive chemotaxis GO:0050918 9.76 HMGB1 DEFB4A CCL3
17 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.76 S100A12 DEFB4A CXCL8 CXCL1
18 toll-like receptor signaling pathway GO:0002224 9.75 TLR4 SFTPD HMGB1
19 positive regulation of interleukin-1 beta secretion GO:0050718 9.74 TLR4 HMGB1 CCL3
20 acute-phase response GO:0006953 9.73 IL6 IL22 CRP
21 defense response to bacterium GO:0042742 9.73 TLR4 SLPI SFTPD S100A12 ELANE DEFB4A
22 respiratory gaseous exchange GO:0007585 9.72 SFTPD SFTPB ELN
23 negative regulation of interferon-gamma production GO:0032689 9.7 TLR4 SCGB1A1 HMGB1
24 positive regulation of interleukin-8 production GO:0032757 9.69 TLR4 HMGB1 CALCA
25 negative regulation of osteoclast differentiation GO:0045671 9.67 TLR4 CCL3 CALCA
26 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.65 TLR4 HMGB1
27 negative regulation of lipid storage GO:0010888 9.64 IL6 CRP
28 cellular response to lipopolysaccharide GO:0071222 9.63 TLR4 IL6 HMGB1 CXCL8 CXCL1 CSF3
29 monocyte chemotaxis GO:0002548 9.62 S100A12 IL6 CCL3 CALCA
30 immune response GO:0006955 9.56 TLR4 SLPI IL6 DEFB4A CXCL8 CXCL1
31 negative regulation of chemokine biosynthetic process GO:0045079 9.54 IL6 ELANE
32 inflammatory response GO:0006954 9.32 TLR4 S100A12 IL6 IL22 HMGB1 CXCL8

Molecular functions related to Bacterial Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.43 CXCL8 CXCL1 CCL3
2 chemoattractant activity GO:0042056 9.33 HMGB1 DEFB4A CCL3
3 RAGE receptor binding GO:0050786 9.32 S100A12 HMGB1
4 cytokine activity GO:0005125 9.17 IL6 IL22 HMGB1 CXCL8 CXCL1 CSF3
5 lipopolysaccharide binding GO:0001530 9.13 TLR4 SFTPD HMGB1
Sources

Sources for Bacterial Pneumonia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....